Neonmind’s NEO-002 synthetic psilocybin applicant will likely be studied as a very low-dose cure to control and suppress affected individual urge for food. The organization has secured pharmaceutical quality synthetic psilocybin from Psygen and anticipates initiating a Section I/II evidence-of-principle study for NEO-001 while in the close to upcoming. https://maximx467xfl6.luwebs.com/profile